A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Avelumab (Primary) ; Trabectedin (Primary)
- Indications Leiomyosarcoma; Liposarcoma
- Focus Adverse reactions
- 28 Sep 2017 Status changed from not yet recruiting to recruiting.
- 08 Sep 2017 Planned End Date changed from 15 Mar 2020 to 15 Sep 2020.
- 08 Sep 2017 Planned primary completion date changed from 15 Apr 2018 to 15 Oct 2018.